Empirical antimicrobial therapy for traveler's diarrhea

Clin Infect Dis. 2000 Oct;31(4):1079-83. doi: 10.1086/318119. Epub 2000 Oct 25.

Abstract

Over 7 million cases of traveler's diarrhea, defined as the passage of > or = 3 unformed stools in a 24-h period, occur each year among visitors to developing countries. Bacterial enteric pathogens are the most common etiologic agents isolated. Preliminary clinical results for patients with diarrhea predominantly caused by Campylobacter species have shown that azithromycin may be an effective alternative to fluoroquinolones for the treatment of traveler's diarrhea.

Publication types

  • Review

MeSH terms

  • Anti-Bacterial Agents / therapeutic use
  • Anti-Infective Agents / therapeutic use*
  • Azithromycin / therapeutic use
  • Bacterial Infections / drug therapy
  • Campylobacter Infections / drug therapy
  • Diarrhea / drug therapy*
  • Fluoroquinolones
  • Humans
  • Travel*
  • Trimethoprim, Sulfamethoxazole Drug Combination / therapeutic use

Substances

  • Anti-Bacterial Agents
  • Anti-Infective Agents
  • Fluoroquinolones
  • Trimethoprim, Sulfamethoxazole Drug Combination
  • Azithromycin